Saudi Arabia’s Professional Medical Expertise Company, known as ProMedEx, has renewed an 84 million riyal Islamic financing package with Riyad Bank, extending a facility the company says will support existing projects and planned business expansion. The package is equivalent to about $22.4 million and is split into SAR 6.5 million in bank guarantee facilities, SAR 22.5 million in letters of credit and SAR 55 million in tawarruq financing.
The renewal keeps in place a funding structure that has become increasingly important for a medical devices and supplies distributor serving government and private hospitals across Saudi Arabia. ProMedEx said the financing duration is 12 months. Disclosures carried by market platforms show the company provided a promissory note worth SAR 88.4 million and a corporate guarantee from Al-Omran Holding as security.
The announcement also underlines how the facility has expanded over time. In October 2024, ProMedEx obtained Shariah-compliant financing from Riyad Bank worth SAR 74.5 million, made up of the same SAR 6.5 million in guarantees, SAR 22.5 million in letters of credit and a lower SAR 45 million tawarruq component. By March 2025, the company disclosed that it had renewed the facility and raised the limit by SAR 10 million to SAR 84 million. Thursday’s filing indicates that the SAR 84 million level has now been renewed again rather than enlarged further.
That chronology matters because it shows a company moving from securing working capital to preserving a broader borrowing capacity while it scales. For a distributor of medical technology, letters of credit are especially significant because imported devices and consumables often require dependable trade-finance lines. Bank guarantees also help in project execution, particularly where public-sector healthcare contracts involve performance commitments and staged delivery terms. The tawarruq portion gives the company additional liquidity for procurement and operating needs. This mix suggests the facility is not merely a balance-sheet formality but a tool tied closely to day-to-day business operations.
ProMedEx operates in a segment that has benefitted from Saudi Arabia’s broader healthcare modernisation drive. Saudi Exchange describes the company as an authorised representative of medical-device manufacturers engaged in importing, storing and distributing medical devices and supplies, including electromechanical equipment, diagnostic devices, software and maintenance services. Its business centres on supplying medical implants, devices and high-technology consumables to government and private hospitals and medical facilities across the Kingdom. The company’s own website says it was established in 2011 and aligns its activity with the government’s Vision 2030 healthcare goals. Vision 2030’s Health Sector Transformation Programme places strong emphasis on improving access, modernising facilities and equipment, and expanding private-sector participation.
The financial backdrop helps explain why maintaining access to bank funding could matter. Saudi Exchange data for the company’s 2025 annual results show revenue of about SAR 418.8 million, up from roughly SAR 313.2 million a year earlier, while attributable net profit rose to about SAR 41.7 million from SAR 27.6 million. Market reports tied that improvement to new agency relationships, improved operational efficiency, higher profit margins and better sales-force productivity. Yet stronger earnings do not remove the need for financing in a business where inventory, imported equipment, contract execution and receivables can place pressure on cash conversion cycles.
ProMedEx has also signalled a preference to conserve liquidity. On March 31, the company said its board had decided not to distribute dividends for the 2025 financial year. Saudi Exchange records show the company cited expansion of current and future operations, preservation of liquidity and strengthening of its financial position as reasons for withholding payouts. Taken together with the facility renewal, that points to a management approach geared more towards funding growth and maintaining flexibility than returning cash to shareholders in the short term.
For Riyad Bank, the deal fits within a wider corporate and small-business financing push. The bank’s investor-relations materials show it remains a major listed lender regulated by the Saudi Central Bank, while its corporate banking information states it held a 21.5% market share in MSME financing in Saudi Arabia by the end of the third quarter of 2024. That does not make ProMedEx a small enterprise by default, but it does indicate Riyad Bank’s broader appetite for structured domestic financing and sector-linked lending relationships.
The renewal keeps in place a funding structure that has become increasingly important for a medical devices and supplies distributor serving government and private hospitals across Saudi Arabia. ProMedEx said the financing duration is 12 months. Disclosures carried by market platforms show the company provided a promissory note worth SAR 88.4 million and a corporate guarantee from Al-Omran Holding as security.
The announcement also underlines how the facility has expanded over time. In October 2024, ProMedEx obtained Shariah-compliant financing from Riyad Bank worth SAR 74.5 million, made up of the same SAR 6.5 million in guarantees, SAR 22.5 million in letters of credit and a lower SAR 45 million tawarruq component. By March 2025, the company disclosed that it had renewed the facility and raised the limit by SAR 10 million to SAR 84 million. Thursday’s filing indicates that the SAR 84 million level has now been renewed again rather than enlarged further.
That chronology matters because it shows a company moving from securing working capital to preserving a broader borrowing capacity while it scales. For a distributor of medical technology, letters of credit are especially significant because imported devices and consumables often require dependable trade-finance lines. Bank guarantees also help in project execution, particularly where public-sector healthcare contracts involve performance commitments and staged delivery terms. The tawarruq portion gives the company additional liquidity for procurement and operating needs. This mix suggests the facility is not merely a balance-sheet formality but a tool tied closely to day-to-day business operations.
ProMedEx operates in a segment that has benefitted from Saudi Arabia’s broader healthcare modernisation drive. Saudi Exchange describes the company as an authorised representative of medical-device manufacturers engaged in importing, storing and distributing medical devices and supplies, including electromechanical equipment, diagnostic devices, software and maintenance services. Its business centres on supplying medical implants, devices and high-technology consumables to government and private hospitals and medical facilities across the Kingdom. The company’s own website says it was established in 2011 and aligns its activity with the government’s Vision 2030 healthcare goals. Vision 2030’s Health Sector Transformation Programme places strong emphasis on improving access, modernising facilities and equipment, and expanding private-sector participation.
The financial backdrop helps explain why maintaining access to bank funding could matter. Saudi Exchange data for the company’s 2025 annual results show revenue of about SAR 418.8 million, up from roughly SAR 313.2 million a year earlier, while attributable net profit rose to about SAR 41.7 million from SAR 27.6 million. Market reports tied that improvement to new agency relationships, improved operational efficiency, higher profit margins and better sales-force productivity. Yet stronger earnings do not remove the need for financing in a business where inventory, imported equipment, contract execution and receivables can place pressure on cash conversion cycles.
ProMedEx has also signalled a preference to conserve liquidity. On March 31, the company said its board had decided not to distribute dividends for the 2025 financial year. Saudi Exchange records show the company cited expansion of current and future operations, preservation of liquidity and strengthening of its financial position as reasons for withholding payouts. Taken together with the facility renewal, that points to a management approach geared more towards funding growth and maintaining flexibility than returning cash to shareholders in the short term.
For Riyad Bank, the deal fits within a wider corporate and small-business financing push. The bank’s investor-relations materials show it remains a major listed lender regulated by the Saudi Central Bank, while its corporate banking information states it held a 21.5% market share in MSME financing in Saudi Arabia by the end of the third quarter of 2024. That does not make ProMedEx a small enterprise by default, but it does indicate Riyad Bank’s broader appetite for structured domestic financing and sector-linked lending relationships.
Topics
Saudi Arabia